3234 Others have found no significant reduction in BP with GLP-1RA treatment
Nevertheless, uncritical enthusiasm is unwarranted given the pervasive heterogeneity of existing trials, the profound dependence of therapeutic effects on formulation characteristics, and the inherent limitations of predominantly short-duration interventions in a disease defined by decades of progressive metabolic deterioration
The study found that within 90 minutes, there was a significant increase in both GLP-1 and insulin secretion
Case description: We report a case of a 28-year-old woman presenting with right arm weakness and dysesthesia
And never inject into a mole, scar, bruise or broken skin
Between August 2021 and mid-July 2024, the FDA had reviewed 288 reports of adverse patient reactions to compounded semiglutide and 108 such reports for tirzepatide